Powder: -20°C for 3 years | In solvent: -80°C for 1 year
GDC-2394, an orally active, selective NLRP3 inhibitor, also targets IL-1β, exhibiting inhibitory concentrations (IC50s) of 0.4 μM (human IL-1β) and 0.1 μM (mouse IL-1β). It effectively hampers NLRP3-induced caspase-1 activity while not affecting NLRC4-dependent inflammasome activation.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 8-10 weeks | $ 1,250.00 | |
50 mg | 8-10 weeks | $ 1,630.00 | |
100 mg | 8-10 weeks | $ 2,480.00 |
Description | GDC-2394, an orally active, selective NLRP3 inhibitor, also targets IL-1β, exhibiting inhibitory concentrations (IC50s) of 0.4 μM (human IL-1β) and 0.1 μM (mouse IL-1β). It effectively hampers NLRP3-induced caspase-1 activity while not affecting NLRC4-dependent inflammasome activation. |
Molecular Weight | 431.51 |
Formula | C20H25N5O4S |
CAS No. | 2238822-07-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
GDC-2394 2238822-07-4 GDC 2394 GDC2394 NS 3956 fumaric acid salt NS3956 fumaric acid salt inhibitor inhibit